Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants-Reference-Cited by-同舟云学术

Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants

Published:2016-03-10 Issue:10 Volume:127 Page:1325-1335
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Chachoua Ilyas¹²,Pecquet Christian¹²,El-Khoury Mira³⁴⁵,Nivarthi Harini⁶,Albu Roxana-Irina¹²,Marty Caroline³⁴⁵,Gryshkova Vitalina¹²,Defour Jean-Philippe¹²,Vertenoeil Gaëlle¹²,Ngo Anna⁷,Koay Ann⁷,Raslova Hana³⁴⁵,Courtoy Pierre J.²,Choong Meng Ling⁷,Plo Isabelle³⁴⁵,Vainchenker William³⁴⁵,Kralovics Robert⁶,Constantinescu Stefan N.¹²

Affiliation:

1. Ludwig Institute for Cancer Research Brussels, Brussels, Belgium;

2. Université Catholique de Louvain and de Duve Institute, Brussels, Belgium;

3. INSERM, Unité Unité Mixte de Recherche 1170, Institut Gustave Roussy, Villejuif, France;

4. Paris-Saclay, Unité Mixte de Recherche 1170, Institut Gustave Roussy, Villejuif, France;

5. Gustave Roussy, Unité Mixte de Recherche 1170, Villejuif, France;

6. CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria; and

7. Experimental Therapeutics Center, Singapore

Abstract

Key Points Calreticulin mutants responsible for myeloproliferative neoplasms specifically activate the thrombopoietin receptor and in turn JAK2. Activation of the thrombopoietin receptor requires the glycan binding site and a novel C-terminal tail of the mutant calreticulin.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/127/10/1325/1392277/1325.pdf

Reference45 articles.

1. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.;Vardiman;Blood,2009

2. JAK/STAT signaling in hematological malignancies.;Vainchenker;Oncogene,2013

3. From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms.;Cazzola;Blood,2014

4. New mutations and pathogenesis of myeloproliferative neoplasms.;Vainchenker;Blood,2011

5. Somatic mutations of calreticulin in myeloproliferative neoplasms.;Klampfl;N Engl J Med,2013

Cited by 259 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pitfalls of using polymerase chain reaction–based assays for JAK2 and CALR exon 9 variant testing in myeloproliferative neoplasms: Knowing when to go the extra mile!;American Journal of Clinical Pathology;2023-10-03

2. Leukemic conversion involving RAS mutations of type 1 CALR-mutated primary myelofibrosis in a patient treated for HCV cirrhosis: a case report;Frontiers in Oncology;2023-09-29

3. BCR::ABL1-negative myeloproliferative neoplasms in the era of next-generation sequencing;Frontiers in Genetics;2023-09-08

4. Molecular pathogenesis of myeloproliferative neoplasms: Where do we stand in 2023?;American Journal of Hematology;2023-08-28

5. Antibody targeting of mutant calreticulin in myeloproliferative neoplasms;Journal of Cellular and Molecular Medicine;2023-08-07